Harmony Biosciences (HRMY) as of March 31, 2026 presents a balance sheet that is strongly positive for equity recovery under a liquidation scenario, though the recoverable value is substantially lower than book equity of $910M due to the intangible-heavy asset composition. Total assets are $1.27B against total liabilities of $361M, yielding GAAP book equity of $910M. Under liquidation haircuts, the picture deteriorates materially: cash and equivalents of $589M recover at par; short-term investments of $52M and long-term investments of $230M (comprising the $472M fair-value investment portfolio) recover near par given investment-grade debt securities; accounts receivable of $108M recover at ~93% (~$100M); inventory of $5M recovers at ~60% (~$3M); finite-lived intangibles net of $83M recover at zero under the liquidation lens (licensed IP, which has no standalone third-party sale value in wind-down); deferred tax assets of $154M recover at zero in liquidation; and other noncurrent assets of $26M recover at low recovery (nominally $5-10M). On the liability side, $160M term loan (face), $150M accrued liabilities, $28M AP, and $6M operating lease liability ($5.8M present value) all stay at face. Estimated liquidation recovery to equity is in the range of $550-620M, representing a meaningful discount to book equity but still substantially positive. MFFAIS-reported CLV of $229M reflects a more conservative haircut methodology; the liquid liquidation value of $337M and operating liquidation value of $342M bracket a mid-range estimate. The most significant balance sheet change versus the prior 10-K (December 31, 2025) is a $163M net decrease in cash (investing outflows of $184M including $179M in securities purchases and $32M in upfront IPR&D license fees to Novitium and MSN, partially offset by $27M in investment maturities), offset by growth in the investment portfolio. The term loan decreased by $5M (quarterly amortization to $160M). Two new upfront license payments ($15M Novitium, $17M MSN) were fully expensed as IPR&D in Q1 2026, creating no balance sheet asset. A disclosed event of default under the TLA Credit Agreement (nonfinancial covenant, subsidiary guarantor delay, dating to July 2025) was waived by lenders on May 4, 2026; the waiver removes the technical acceleration risk that would have pulled $160M of debt to current at face value, though all principal was already tracked as current/noncurrent per contractual schedule. The $25M contingent escrow deposit required under the MSN Agreement (due within 9 months of February 25, 2026 effective date, refundable if USPTO does not approve by November 2027) is not yet reflected as a balance sheet liability or restricted cash in the current period filing, and is not separately XBRL-tagged — this represents an off-balance-sheet contingency that would reduce cash available to equity in liquidation if the deposit has been or will be made. Filing discusses this MSN escrow obligation in MD&A but does not separately tag it in XBRL.
▼ Community Notes